Allergan Settles with Amneal, Allows Alzheimer’s Generics in 2025

Allergan and Amneal have reached a settlement that will allow the latter to market generics of the Alzheimer’s drug Namzaric in 2025.

The terms of settlement will still undergo review by the U.S. Federal Trade Commission, Allergan said, but as it stands the agreement grants Amneal a license to market the generics starting on Jan. 1, 2025.

The companies did not disclose further terms of the settlement of litigation that began in 2015, when Allergan sued Amneal in response to its ANDA for development of a generic of Namzaric.